Senior AI Engineer Software Engineer Government Technology is a AI Engineer role (full-time). with ICON. in REMOTE, AUSTIN, US. Compensation shown: $193K–$265K. Imported listing (source: jobs-radar.com). Apply on the employer's site (jobs-radar.com).
Imported listing (source: jobs-radar.com) · Apply on jobs-radar.com
The sections below reproduce the third-party job description for reference. AIEngineer.careers does not write or control this text.
Imported job description
Sourced from jobs-radar.com
ICON is looking for a Senior AI Engineer to join its Government Technology team, focusing on building agentic AI systems and LLM-powered features for construction technology. The role involves designing multi-agent pipelines, RAG systems, and tool-use architectures. This position is remote with occasional travel to Austin, TX.
Responsibilities
Design and build agentic AI systems that automate complex, multi-step workflows
Develop LLM-powered features and products using foundation models and APIs (e.g., Anthropic, OpenAI)
Architect and implement multi-agent pipelines, tool-use systems, and MCP integrations
Build robust RAG systems including document ingestion, chunking, embeddings, and vector retrieval
Collaborate with teams to identify AI automation opportunities and ship products
Own full development lifecycle: prototyping, evaluation, deployment, iteration
Serve as technical resource and mentor on agentic AI best practices
Stay at leading edge of agentic AI landscape and bring techniques to production
Requirements
8+ years of professional software engineering experience
Experience building and shipping production-grade products using LLMs and agentic frameworks
ICON plc is a global clinical research organization (CRO) that provides outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations. The company offers a wide range of solutions, including clinical development strategy, trial design, study execution, and commercialization support to accelerate the development of new treatments.